This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Health stocks followed the broader markets into a refreshing green spell on Thursday amid medical technology and diagnostics earnings.

Big biotechs Amgen (AMGN) and Biogen Idec (BIIB) were up trading up more than 2% each. Also Gilead (GILD) and Genzyme (GENZ) added 1.4% and 1.2% respectively.

In fact, every stock on the Amex biotechnology index, which was up 2.1% at 760.94, read green midday Thursday except for biotech behemoth Genentech (DNA). Its shares were incidentally off by 0.4%, at $67.92.

Away from biotechs, Orthopedic product maker Orthofix International NV (OFIX - Get Report) said Thursday that its first-quarter profit fell to $3.6 million, or 21 cents a share, from $6.3 million, or 37 cents a share, in the year-ago period.

Revenue rose 9% to $128 million from $117 million, beating expectations of analysts polled by Thomson Financial who expected profit of 9 cents a share on revenue of $122.5 million. The beat prompted a 14.6% rise in the stock, to $35.25.

Also up, Natus Medical (BABY - Get Report) 6.5% to $20.94 after beating first-quarter earnings estimates and raising guidance. The newborn-care product maker said it earned $2.6 million, or 11 cents a share, up 73% from $1.5 million, and 7 cents a share, in the year-ago quarter. Revenue climbed 36% to $36.9 million, analysts surveyed by Thomson Financial were looking for 10 cents a share, on $35.5 million in revenue.

Natus also upped its first-quarter expectations to 72 cents a share on revenue of $162 million, from previous guidance of 70 cents and $161 million.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BABY $48.79 1.90%
HOLX $39.93 -0.20%
OFIX $39.60 0.53%
SGMO $7.57 4.40%
AAPL $118.05 -0.70%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs